Haemoglobin A1c – A Marker for Complications of Type 2 Diabetes: The Experience from the UK Prospective Diabetes Study (UKPDS)

Publisher Website
Google Scholar
Abstract
Haemoglobin A(1c) (HbA(1c)) is the preeminent factor for quantifying the risk of complications in patients with diabetes and for monitoring glycaemia. Intervention to lower blood glucose in the two landmark clinical trials, the UK Prospective Diabetes Study (UKPDS) and the Diabetes Control and Complications Trial (DCCT), led to a reduction in the microvascular complications of diabetes. Glycaemic status could be compared in the UKPDS and DCCT as the BioRad Diamat HPLC analyser, as used in the DCCT, was introduced in 1989 for measurement of HbA(1c) in the UKPDS, after liaison with the DCCT. Results from other methods used for measurement of glycated haemoglobin during the UKPDS were aligned to this method. The BioRad Diamat analyser in the central laboratory for the UKPDS, reference range 4.56.2% HbA(1c), was certified as comparable to the DCCT by the National Glycohemoglobin Standardization Program in 1998. A median difference in HbA(1c) of 0.9% was maintained over 10 years between the intensively and conventionally treated groups in the UKPDS (7.0% vs. 7.9% HbA(1c)) despite HbA(1c) increasing over time. Clinical care was transferred to general practitioners after the end of the main glucose control study for poststudy monitoring. Over the first 3 years of poststudy monitoring, HbA(1c) rose slightly in the previously intensively treated group with no appreciable increase in the conventional group, due to intensification of therapy. At near-normal HbA(1c), 10% updated mean HbA(1c). Relationships between the risk of complications of type 2 diabetes and updated mean HbA(1c) had no observable thresholds. The UKPDS risk engine derived from the UKPDS database calculates coronary heart disease risk using HbA(1c) as a continuous variable and could now replace the Framingham equations for patients with type 2 diabetes.